EVJ presents growing evidence for regenerative medicine

Processing autologous conditioned serum
for intra-articular injection 
(photo courtesy of Lynn Pezzanite)

Regenerative therapies have become more widely used in equine practice over the past 20 years. They involve treatments that aim to repair or replace damaged tissues and promote healing using the body's natural regenerative capabilities. These therapies are increasingly used to treat injuries, particularly those affecting tendons, ligaments, joints, and cartilage.

 

Despite considerable advances in the field, the true efficacy of veterinary regenerative medicine is still questioned in many instances. To enable easy access to the latest knowledge on the topic, the Equine Veterinary Journal (EVJ) has published a ‘Special Collection’.

Guest edited by Lynn Pezzanite, the Special Collection contains the ‘Top 10’ recent publications from EVJ relating to regenerative therapies over the past five years which may help practitioners select one treatment over another for a specific clinical indication.

 

The term ‘regenerative therapies’ is a broad definition for innovative medical therapies that enable the body to repair, replace, restore, and regenerate damaged or diseased cells, tissues, and organs, while ‘biological products’ are those made from living material (human, animal, plant, microorganisms) used to treat or prevent disease. 

 

Options available to clinicians in equine practice include point-of-care blood or tissue derived products (autologous – derived from the same individual) including platelet rich plasma (PRP), autologous conditioned serum (ACS or interleukin receptor antagonist protein/IRAP), autologous protein solution (APS), bone marrow aspirate concentrate (BMAC or stromal vascular fraction) or cultured stromal cell-based products (autologous or allogeneic – derived from a different individual of the same species). 

 

“Equine practitioners have access to use regenerative medicine to treat joint and soft tissue disorders as well as a variety of other conditions such as wounds, ophthalmic or theriogenology indications,” said Lynn. “However, in some instances due to lack of rigour in clinical study design, lack of demonstrated consistency in product formulation and lack of regulatory oversight that would assure appropriate standards, the true efficacy of some therapies remains controversial. We aim for this special collection to bring some clarity, to aid vets in their treatment choices.”

 

To see the Special Collection, go to::

 

https://beva.onlinelibrary.wiley.com/hub/journal/20423306/homepage/regenerative-therapies-collection